All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
#EHA2024: Hodgkin lymphoma and T-cell lymphoma
Catch up with our live social media coverage of Hodgkin lymphoma and T-cell lymphoma from the European Hematology Association (EHA) 2024 Hybrid Congress.
June 13—16
Bookmark this article
To update you on the exciting content presented at the European Hematology Association (EHA) 2024 Hybrid Congress, we have collated our social media coverage. Catch up with our live social media relating to Hodgkin lymphoma and T-cell lymphoma, here.
CONGRESS #EHA2024 | Peter Borchmann #cioabcd presents the final analysis of phase III #HD21 trial of PET2-individualized BrECADD regimen vs intensified BEACOPP in patients with advanced-stage #HodgkinLymphoma. BrECADD had superior efficacy (PFS 94.3% vs 90.9% at 4 yr) with… pic.twitter.com/nDfB7Zx3kf
— Lymphoma Hub (@lymphomahub) June 16, 2024
CONGRESS #EHA2024 | Poster | Chunyan Xiao at Chongqing university cancer hospital reports interim results from a phase 2 trial of chidamide with azacitidine and CHOP treatment plus auto-ASCT for patients with newly diagnosed PTCL. N=45, ORR=85.3%, CR=48.5%. Post allo-HSCT, n=17,… pic.twitter.com/8Qui5sjay6
— Lymphoma Hub (@lymphomahub) June 15, 2024
CONGRESS #EHA2024 | Pier Luigi Zinzani @Unibo reports outcomes from the VALENTINE-PTCL01 study of valemetostat 200 mg/day in pts with R/R PTCL. Primary endpoint; overall ORR was 44%; ORR for pts with 1, 2, and ≥ 3 prior LOT were 52.8%, 46.7%, and 35.8%, respectively. ORR trended… pic.twitter.com/lyb7rLScDz
— Lymphoma Hub (@lymphomahub) June 16, 2024
CONGRESS #EHA2024 | Poster | Mingci Cai at Shanghai institute of hematology reports phase 2 study of tazemetostat plus amdizalisib in pts with R/R lymphomas. N=21. Azemetostat plus amdizalisib shown promising efficacy and safety in R/R lymphoma, particularly in PTCL and DLBCL,… pic.twitter.com/rInM2KkFCb
— Lymphoma Hub (@lymphomahub) June 15, 2024
CONGRESS #EHA2024 | Evgenii Shumilov presents analysis of the EBMT lymphoma working party registry providing large-scale real-world data of auto- and allo-SCT in pts with T-cell lymphoma over 20 yrs. Transplantation remains the promising treatment for pts with R/R T-cell… pic.twitter.com/VX0WSWk4N7
— Lymphoma Hub (@lymphomahub) June 16, 2024
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
60 votes - 49 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox